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INTRODUCTION
The nutritional state of patients with liver cirrhosis
is frequently poor, and about 70% of patients show
some signs of malnutrition (1). Patients with liver
cirrhosis exhibit abnormal metabolism, including
increased fat oxidation and decreased glucose
oxidation (2-4). Increased fat oxidation manifests
as starvation after an overnight fast because of a
lack of glycogen stores in patients (5). Furthermore,
liver cirrhosis frequently impairs postprandial glu-
cose tolerance, with 20 to 40% of patients develop-
ing diabetes mellitus. Therefore, supplementation of
a late evening snack (LES) with a low glycemic in-
dex (GI) may be advisable in such patients to pre-
vent early-onset starvation and energy deficiency and
to maintain a good nutritional status.
The GI was introduced by Jenkins, et al. as a
quantitative assessment of foods based on the
postprandial blood glucose response (6, 7), and is
expressed as a percentage of the response to an
equivalent carbohydrate portion of a reference food,
such as white bread or glucose (8). The novel en-
teral liquid formula designated Inslow was prepared
by replacing dextrin in the standard balanced for-
mula (SBF) with palatinose at 55.7% of the carbo-
hydrate content (Table 1). Palatinose was completely
cleaved and absorbed, and the hydrolysis of palati-
nose by a homogenate of human intestinal mucosa
was one-fourth that of sucrose (9, 10). A previous
study in our laboratory demonstrated that the in-
crease in plasma glucose and insulin after Inslow
ingestion was significantly smaller than that after
SBF ingestion (11, 12). In this study, because lack
of energy intake was assessed in a patient with liver
cirrhosis and diabetes controlled with insulin, 250
kcal of Inslow was administered.
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CASE REPORT
The patient was a 66-year old man who was
diagnosed with hepatocellular carcinoma, liver cir-
rhosis, hepatitis B and C virus infection and diabe-
tes, and had received a hepatectomy in 1997. In-
sulin treatment was started four months later, re-
sulting in an increase in body weight. The patient
was treated repeatedly with percutaneous ethanol
injection therapy, radio frequency ablation, tran-
scatheter arterial embolization, and chemotherapy
in 2004-2006.
In July 2006, his body weight, height and body
mass index were 71.3 kg, 160 cm and 27.9 kg/m2,
respectively, although his ideal body weight was
56.3 kg. Fasting blood glucose levels were controlled
to about 90 to 105 mg/dl by injection of 38 units of
insulin (Novorapid : 22 units before breakfast, 4 units
before lunch and 12 units before dinner). ESPEN
guidelines (13) recommend a non-protein energy
of 25-35 kcal/kg for cirrhotic patients without
malnutrition. His required energy intake was esti-
mated as 1,500-1,700 kcal/d by using either indirect
calorimetric analysis or the Harris-Benedict equa-
tion. Because his actual energy intake was 82548
kcal/d, an in increase in energy intake without an
elevation in blood glucose level was absolutely
required for this patient. As the first step of nutri-
tional care for this patient, an intake of 250 kcal of
Inslow, a liquid balanced formula with a low glycemic
index manufactured by the Meiji Dairy Company,
as an LES was recommended by the nutritional
support team in Tokushima University Hospital.
As shown in Fig. 1, the patient’s energy intake
gradually increased to 104977 kcal/d after 1 week of
treatment, 119548 kcal/d after 2 weeks, 134042
kcal/d after 3 weeks, 121977 kcal/d after 4 weeks,
151760 kcal/d after 5 weeks and reached 156766
kcal/d after 6 weeks. His fasting glucose level did not
change, remaining at about 100 mg/dl throughout
this period. Interestingly, the amount of insulin
administered decreased to 32 units (Novorapid : 20
units before breakfast, 4 units before lunch and 8
units before dinner) in the third week of treatment
and to 28 units (Novorapid : 16 nits before breakfast,
Fig. 1 Energy intake, fasting blood glucose level and amount of insulin injected during the course of nutritional treatment
Table 1 Composition of Inslow and standard balanced
formula (SBF)
Inslow Standard balanced formula(SBF)
Energy 1kcal/ml 1kcal/ml
Protein 20.0 % 16.0 %
Fat 29.7 % 25.0 %
SFA 9.5 % 9.0 %
MUFA 68.5 % 45.0 %
PUFA 16.8 % 40.0 %
Carbohydrate 50.3 % 59.0 %
Maltodextrin 22.8 % Sucrose 2.8 %
Xylitol 8.9 % Dextrin 97.2 %
Paratinose 68.3 %
Abbreviations : SFA, saturated fatty acid ; MUFA, mono-
unsaturated fatty acid ; PUFA, polyunsaturated fatty acid.
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4 units before lunch and 8 units before dinner) in the
fifth week of treatment. Thus, 10 units of insulin was
saved by nutritional therapy, even though the daily
energy intake increased by about 700 kcal.
The daily pattern of blood glucose fluctuated highly
in the initial period of nutritional treatment, but
interestingly blood glucose levels became constant
in the fifth week of treatment (Fig. 2). The cumula-
tive area under the curve (AUC) for daily blood glu-
cose in the fifth and sixth weeks of nutritional treat-
ment was significantly lower than that in the first and
second weeks (Fig. 3). Laboratory data, including
serum levels of albumin, α-fetoprotein and protein
induced by vitamin K absence of antagonist-II
(PIVKA-II), lactate dehydrogenase activity and other
biomarkers of hepatic function and nutritional status,
did not show any significant changes after this nutri-
tional treatment (Table 2).
Table 2 Laboratory data during the course of nutritional
treatment
Before Week of treatment
1st 2nd 3rd 4th 5th 6th
WBC (103/μl) 3.3 0.9 4 3.4 3.3 3.3 3.6
RBC (106/l) 3.06 2.7 2.57 2.61 2.68 2.68 2.9
HGB (g/dl) 10.3 9.3 8.8 9.7 10.1 10.1 10.6
HCT (%) 29.2 25.5 25 27.7 29 29 32
PLT (103/μl) 93 34 62 105 115 115 85
AST (IU/l) 23 32 26 26 34 34 31
ALT (IU/l) 15 19 15 13 13 13 17
LDH (IU/l) 133 177 190 181 240 240 170
T-BIL (mg/dl) 0.6 0.9 0.5 0.7 0.9 0.9 0.8
D-BIL (mg/dl) 0.1
ALP (IU/l) 302 301 346 347 324 324 291
γ-GPT (IU/l) 52 49 45 58 73 73 90
TP (g/dl) 6.2 6 5.8 6.5 6.6 6.6 6.4
ALB (g/dl) 2.7 2.3 2.5 2.6 2.6 2.6
BUN (mg/dl) 17 18 14 13 13 13 14
Crea (mg/dl) 0.65 0.55 0.55 0.6 0.52 0.52 0.58
Na (mEq/l) 139 139 143 140 140 140 138
K (mEq/l) 4.6 4.4 4.6 4.7 4.6 4.6 4.5
Cl (mEq/l) 104 104 107 108 105 105 104
ChE (IU/l) 98
AMY (IU/l) 49 22
A/G 0.77 0.66 0.66 0.65 0.65 0.68
CRP (mg/dl) 1.33 4.5 1.27 0.89 0.78 0.78 0.21
AFP (ng/ml) 4960 6010
PIVKA-II (mAU/ml) 1310 376
ICG (%) 30
Abbreviations : WBC : white blood cell, RBC : red blood cell, HGB :
hemoglobin, HCT : hematocrit, PLT : platelet, ALT : alanine
aminotransferase, AST : aspartate aminotransferase, LDH : lactate
dehydrogenase, T-BIL : total bilirubin, D-BIL : direct bilirubin,
ALP : alkaline phosphatase, γ-GTP : γ-glutamyl transpeptidase,
TP : total protein, ALB : albumin, BUN : blood urea nitrogen,
Crea : creatinine, Na : sodium, K : potassium, Cl : chloride, ChE :
choline esterase, AMY : amylase, A/G : albumin to globulin ratio,
CRP : C-reactive protein, AFP : α-fetoprotein, PIVKA-II : protein
induced by vitamin K absence of antagonist-II, ICG : indocyanin
green test
Fig. 2 Daily pattern of blood glucose levels before and during
the fourth and sixth weeks of nutritional treatment.
A : Before, B : 4th week, C : 6th week
Fig. 3 Cumulative area under the curve for daily blood glucose
during the course of nutritional treatment.
Values are meansSE (n=14). * : p0.05 (vs. before treatment,
by student t test)
A
B
C
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DISCUSSION
Characteristic hormonal and metabolic alterations,
including depleted hepatic glycogen storage and
impaired hepatic glycogenolysis, have been shown
in cirrhotic subjects (14-18). An LES has been shown
to improve fuel utilization (19, 20) and nitrogen
economy (21, 22). An LES comprising a liquid nu-
trient (Ensure Liquid) has also been shown to in-
crease RQ and carbohydrate oxidation rates (23). For
these reasons, LES administration was recommended
to minimize early starvation for overnight fasting in
this patient because of an insufficient energy intake.
Cirrhotic patients usually exhibit postprandial
hyperglycemia and hyperinsulinemia. Depending on
the etiology, degree of liver damage and diagnostic
criteria, the reported incidence of impaired glucose
tolerance in liver cirrhosis varies between 60 and
80% and that of diabetes varies between 20 and 63%
(24). Studies using the ‘euglycemic hyperinsulinemic
glucose clamp technique’ show that nearly all pa-
tients with cirrhosis have peripheral insulin resistance
at 30-60% of the control level (25, 26). Peripheral
insulin resistance in cirrhosis is characterized by
decreased glucose transport and reduced glycogen
synthesis in skeletal muscle, whereas the insulin-
induced increases in glucose phosphorylation,
glycolysis and glucose oxidation are normal in
cirrhosis (27-30). Similarly, the increased amounts
of insulin cannot normalize the capacity of glycogen
synthesis, but disproportionally increase lactate
production in cirrhosis (29).
The energy intake of this patient increased from
825 kcal to 1567 kcal through nutritional therapy
with the low GI food Inslow as an LES for 6 weeks.
In contrast, the amount of insulin injected decreased
from 38 units to 28 units, indicating a marked
improvement in insulin sensitivity due to Inslow
administration. These findings may explained by
our previous data showing that Inslow suppressed
postprandial hyperglycemia and reduced hepatic and
visceral fat accumulation better than another
commercially available SBF, despite the fact that the
daily food intake remained the same in both groups
over the long term (11). Furthermore, expression
of the PPAR-γ and adiponectine genes in the adipose
tissue was higher in the Inslow group than in the
SBF group (31). The PPAR-γ is a major regulator
of adipocyte differentiation and controls the expres-
sion of various kinds of adipocyte-specific genes
(32). Pharmacological activators of PPAR-γ, such as
thiazolidinedione (TZD), significantly improve insulin
sensitivity in type 2 diabetes (33). Furthermore,
Inslow enhanced expression of the β-oxidation
enzyme gene in adipose tissue. Therefore, it was
suggested that Inslow promotes an insulin-sparing
effect, raises the number of small adipocytes, and
increases the expression of PPAR-γ mRNA to
stimulate fatty acid utilization.
Inslow supplementation as an LES for 6 weeks did
not improve the laboratory data of hepatic function
and nutritional status. However, we conclude that
the long-term administration of Inslow as an LES
may be a useful and novel treatment for increasing
energy intake and improving insulin resistance in
cirrhotic patients, although further studies are re-
quired.
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